Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated ...

Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was ‘minimising disease activity with the fewest treatment-associated toxicities and slowing or ...

Background The short-term and long-term outcome of inflammatory neuropsychiatric SLE (NPSLE) with immunosuppressive treatment is largely unknown. We used clinical data from our tertiary referral ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice. Methods Seventy-two patients with active SLE who received telitacicept ...

Objective To evaluate the performance of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria in a cohort of patients with biopsy-confirmed ...

Objective To investigate the role of curcumin in the treatment of lupus nephritis (LN) by inhibiting the migration of neutrophils and the underlying mechanism involved. Methods Two lupus mouse models, ...

Objectives While diffuse alveolar haemorrhage (DAH) is recognised as a life-threatening complication of systemic lupus erythematosus (SLE), little is known about its risk factors and response to ...

Objective To determine frequency, demographic and treatment characteristics of patients with an overlapping second autoimmune illness (2nd AI). Methods We analysed two cohorts containing 897 patients ...

Objective Assess the safety and efficacy of belimumab in older adults with SLE. Methods This post hoc integrated analysis (GSK Study 116559) included safety data from six randomised, ...

Objective To character the molecular landscape of patients with type 1 and type 2 SLE by analysing gene expression profiles from peripheral blood. Methods Full transcriptomic RNA sequencing was ...

Disease modification has become a well-established concept in several therapeutic areas; however, no widely accepted definition of disease modification exists for SLE. We reviewed established ...

Objective To evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of iberdomide in patients with SLE. Iberdomide is a high-affinity cereblon ligand that targets the hematopoietic ...